The trading price of Bioline Rx Ltd ADR (NASDAQ:BLRX) floating higher at last check on current market day and closing at $0.43, 5.93% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $0.4208 and $0.4489. In examining the 52-week price action we see that the stock hit a 52-week high of $1.93 and a 52-week low of $0.39. Over the past month, the stock has lost -30.81% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bioline Rx Ltd ADR, whose market valuation is $34.32 million at the time of this writing, is expected to release its quarterly earnings report on 2024-Nov-04. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.1 per share this quarter, however they have predicted annual earnings per share of -0.35 for current year and -0.38 for next year.
Analysts have forecast the company to bring in revenue of 4.12M for the current quarter, with the likely lows of 2.86M and highs of 5.85M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 20.29M.
On the technical side, indicators suggest BLRX has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned BLRX a recommendation rating is 1. Out of them, 0 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Bioline Rx Ltd ADR (BLRX) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that BLRX’s price is currently -7.42% off the SMA20 and -25.72% off the SMA50. The RSI metric on the 14-day chart is currently showing 36.09, and weekly volatility stands at 12.02%. When measured over the past 30 days, the indicator reaches 12.13%. Bioline Rx Ltd ADR (NASDAQ:BLRX)’s beta value is currently sitting at 1.46, while the Average True Range indicator is currently displaying 0.05.
To see how Bioline Rx Ltd ADR stock has been performing today in comparison to its peers in the industry, here are the numbers: BLRX stock’s performance was 5.93% at last check in today’s session, and -67.99% in the past year.
An evaluation of the daily trading volume of Bioline Rx Ltd ADR (NASDAQ:BLRX) indicates that the 3-month average is 286.44K. However, this figure has increased over the past 10 days to an average of 0.39.
Currently, records show that 79.99 million of the company’s shares remain outstanding. The insiders hold 0.56% of outstanding shares, whereas institutions hold 5.32%. The stats also highlight that short interest as of 2024-10-15, stood at 0.62 million shares, resulting in a short ratio of 1.94 at that time. From this, we can conclude that short interest is 78.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were up slightly from the previous month’s figure, which was 0.18 million. However, since the stock’s price has seen -72.68% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
